Floatz logo

296 assets in Myelodysplastic Syndrome

Therapeutic assets addressing Myelodysplastic Syndrome, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Cyclophosphamide
Myelodysplastic Syndrome
Sawa Ito, MDP4BB (71)
Busulfanum
Myelodysplastic Syndrome
Sawa Ito, MDP4BB (70)
Cytarabine
Myelodysplastic Syndrome
The First Affiliated Hospital of Soochow UniversityP4BB (70)
Daunomycin
Myelodysplastic Syndrome
OHSU Knight Cancer InstituteP3BB (70)
Fludarabine
Myelodysplastic Syndrome
City of Hope Medical CenterP4BB (70)
Nivestim
Myelodysplastic Syndrome
City of Hope Medical CenterP4BB (70)
Etoposide
Myelodysplastic Syndrome
Memorial Sloan Kettering Cancer CenterP3BB (69)
Idarubicin
Myelodysplastic Syndrome
OHSU Knight Cancer InstituteP4BB (69)
Methotrexate
Myelodysplastic Syndrome
The First Affiliated Hospital of Soochow UniversityP3BB (69)
Romidepsin
Myelodysplastic Syndrome
Sawa Ito, MDP4BB (69)
Sitagliptin
Myelodysplastic Syndrome
Indiana UniversityP2BB (69)
Azacitidine
Myelodysplastic Syndrome
The First Affiliated Hospital of Soochow UniversityP3BB (68)
Cladribine
Myelodysplastic Syndrome
University of FloridaP2/3BB (68)
Clofarabine
Myelodysplastic Syndrome
Memorial Sloan Kettering Cancer CenterP2/3BB (68)
Cyclosporin A
Myelodysplastic Syndrome
City of Hope Medical CenterP3BB (68)
Hydrocortisone
Myelodysplastic Syndrome
Andrew E. Place, MDP3BB (68)
L-Ofloxacin
Myelodysplastic Syndrome
University of ManitobaP3BB (68)
Tacrolimus
Myelodysplastic Syndrome
City of Hope Medical CenterP3BB (68)
Treosulfan
Myelodysplastic Syndrome
Masonic Cancer Center, University of MinnesotaP3BB (68)
Decitabine
Myelodysplastic Syndrome
Washington University School of MedicineP4BB (67)
Gemtuzumab Ozogamicin
Myelodysplastic Syndrome
National Cancer Institute (NCI)P3BB (67)
Quizartinib
Myelodysplastic Syndrome
M.D. Anderson Cancer CenterP2/3BB (67)
Adriamycin
Myelodysplastic Syndrome
Indiana UniversityP2BB (66)
Alemtuzumab
Myelodysplastic Syndrome
University Hospital TuebingenP2/3BB (66)
Astx727
Myelodysplastic Syndrome
Taiho Oncology, Inc.P3BB (66)
Equine Atg
Myelodysplastic Syndrome
DKMS gemeinnützige GmbHP3BB (66)
Melphalan
Myelodysplastic Syndrome
City of Hope Medical CenterP3BB (66)
Mitoxantrone
Myelodysplastic Syndrome
Fred Hutchinson Cancer CenterP3BB (66)
Nivolumab
Myelodysplastic Syndrome
SCRI Development Innovations, LLCP2/3BB (66)
Peripheral Blood Stem Cells, Allogeneic, Cd34 Positive
Myelodysplastic Syndrome
Fred Hutchinson Cancer CenterP2/3BB (66)
Guadecitabine
Myelodysplastic Syndrome
Groupe Francophone des MyelodysplasiesP2BB (65)
Arsenic Trioxide
Myelodysplastic Syndrome
The University of Hong KongP2/3BB (64)
Azacytidine
Myelodysplastic Syndrome
Janssen Research & Development, LLCP3BB (64)
Basiliximab
Myelodysplastic Syndrome
City of Hope Medical CenterP2BB (64)
Crisantaspase
Myelodysplastic Syndrome
St. Jude Children's Research HospitalP3BB (64)
Dexasone
Myelodysplastic Syndrome
Andrew E. Place, MDP3BB (64)
Lenalidomide
Myelodysplastic Syndrome
Medical College of WisconsinP2BB (64)
Posaconazole
Myelodysplastic Syndrome
AstraZenecaP4BB (64)
Rituximab
Myelodysplastic Syndrome
Prelude TherapeuticsP3BB (64)
Thiotepa
Myelodysplastic Syndrome
Sawa Ito, MDP4BB (64)
Amsacrine
Myelodysplastic Syndrome
Heinrich-Heine University, DuesseldorfP3B (63)
Cedazuridine
Myelodysplastic Syndrome
National Cancer Institute (NCI)P3B (63)
Cpx-351
Myelodysplastic Syndrome
National Cancer Institute (NCI)P2/3B (63)
Daratumumab
Myelodysplastic Syndrome
City of Hope Medical CenterP2B (63)
Pomalidomide
Myelodysplastic Syndrome
National Cancer Institute (NCI)P2B (63)
Prednisone
Myelodysplastic Syndrome
Indiana UniversityP2B (63)
Sirolimus
Myelodysplastic Syndrome
City of Hope Medical CenterP3B (63)
Anti-Human T-Lymphocyte Immunoglobulin, Rabbit
Myelodysplastic Syndrome
The First Affiliated Hospital of Soochow UniversityP4B (62)
Asparaginase
Myelodysplastic Syndrome
Children's Oncology GroupP3B (62)
Atorvastatin
Myelodysplastic Syndrome
Loyola UniversityP3B (62)
Showing 1 to 50 of 296 assets
PreviousPage 1 of 6Next